Studies have shown that LLT1 can inhibit the ability of NK cells to target glioma, prostate cancer, squamous cell carcinoma, B-cell lymphomas, lung cancer and triple-negative breast cancer cells. Here, CLEC2D is linked to triple-negative breast carcinoma.